Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | CDK1 | P06493 | 1/20 | 0.42 |
| ▸ | CDK4 | P11802 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | CSNK1D | P48730 | 4/20 | 0.41 |
| ▸ | KDR | P35968 | 3/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | PLK4 | O00444 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.40 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.40 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.40 |
| ▸ | RET | P07949 | 1/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.40 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.40 |
| ▸ | MARK3 | P27448 | 1/20 | 0.40 |
| ▸ | AXL | P30530 | 1/20 | 0.40 |
| ▸ | FLT4 | P35916 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2415641 | 0.91 | CDK2 (0.43) | MAPTCDK1CDK4CDK2KDR | |
| SCHEMBL2419139 | 0.91 | TP53 (0.43) | MAPTCDK1CDK4CDK2CSNK1D | |
| SCHEMBL2423392 | 0.90 | CSNK2A2 (0.43) | MAPTCDK1CDK4CDK2KDR | |
| SCHEMBL2411622 | 0.90 | CSNK1D (0.44) | MAPTCDK1CDK4CDK2CSNK1D | |
| SCHEMBL2417443 | 0.89 | KDR (0.49) | MAPTCDK1CDK4CDK2CSNK1D | |
| SCHEMBL2414027 | 0.89 | MAPT (0.47) | MAPTCDK1CDK4CDK2CSNK1D | |
| SCHEMBL2416285 | 0.89 | MAPT (0.49) | MAPTCDK1CDK4CDK2CLK2 | |
| SCHEMBL2417462 | 0.88 | MAPT (0.46) | MAPTCDK1CDK4CDK2CSNK1D | |
| SCHEMBL2416287 | 0.88 | MAPT (0.46) | MAPTCDK1CDK4CDK2CSNK1D | |
| SCHEMBL2409755 | 0.88 | KDR (0.44) | MAPTCDK1CDK4CDK2CSNK1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7541378-B2 | Condensed heterocyclic pyrazole derivatives as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2009-06-02 | — | — | US | claimed |
| EP-1530573-B1 | CONDENSED HETEROCYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PFIZER ITALIA SRL (IT) | 2008-03-19 | — | — | EP | claimed |
| US-8017643-B2 | Condensed heterocyclic pyrazole derivatives as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-09-13 | — | — | US | disclosed |
| US-20100286223-A1 | Condensed Heterocyclic Pyrazole Derivatives as Kinase Inhibitors | PFIZER ITALIA S.R.L. (IT) | 2010-11-11 | — | — | US | disclosed |
| US-7786048-B2 | Condensed heterocyclic pyrazole derivatives as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2010-08-31 | — | — | US | disclosed |
| US-20090233813-A1 | Condensed Heterocyclic Pyrazole Derivatives as Kinase Inhibitors | PFIZER ITALIA S.R.L. (IT) | 2009-09-17 | — | — | US | disclosed |
| US-7541378-B2 | Condensed heterocyclic pyrazole derivatives as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2009-06-02 | — | — | US | disclosed |
| EP-1530573-B1 | CONDENSED HETEROCYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PFIZER ITALIA SRL (IT) | 2008-03-19 | — | — | EP | disclosed |
| US-20060122249-A1 | Condensed heterocyclic pyrazole derivatives as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286223-A1 | Condensed Heterocyclic Pyrazole Derivatives as Kinase Inhibitors | CDK2, MAP3K19, MAP3K15 | MAPT 2293/4885CDK1 21/4885CDK4 27/4885 |
| US-20060122249-A1 | Condensed heterocyclic pyrazole derivatives as kinase inhibitors | CDK2, MAP3K19, MAP3K15 | MAPT 2293/4885CDK1 21/4885CDK4 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.